You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
|
---|---|
Published in |
Journal of Clinical Oncology, January 1996
|
DOI | 10.1200/jco.1996.14.1.7 |
Pubmed ID | |
Authors |
J M Kirkwood, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum |
Abstract |
Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Belgium | 1 | <1% |
Unknown | 123 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 15 | 12% |
Other | 11 | 9% |
Student > Ph. D. Student | 11 | 9% |
Student > Master | 10 | 8% |
Student > Postgraduate | 9 | 7% |
Other | 22 | 18% |
Unknown | 46 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 23% |
Biochemistry, Genetics and Molecular Biology | 16 | 13% |
Immunology and Microbiology | 8 | 6% |
Agricultural and Biological Sciences | 5 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Other | 13 | 10% |
Unknown | 48 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#1,092,200
of 26,017,215 outputs
Outputs from Journal of Clinical Oncology
#2,658
of 22,362 outputs
Outputs of similar age
#626
of 82,075 outputs
Outputs of similar age from Journal of Clinical Oncology
#1
of 39 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,362 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 82,075 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.